Tavros Therapeutics, co-founded by Kris Wood, PhD, associate professor of pharmacology and cancer biology, and Eoin McDonnell, PhD, a graduate of the Duke University Molecular Cancer Biology PhD Program , has been acquired by Vividion Therapeutics, a subsidiary of global life sciences company Bayer AG. Tavros uses functional genomics to develop more precise and effective therapies for cancer patients.
Tavros and Vividion have engaged in a productive partnership over the past two years and aim to build on their success to date to maximize their ability to bring new treatment options to patients, McDonnell told NC Biotech .
Learn more about the acquisition.